The interest of multiple sclerosis attacks. Physiopathology and therapy;Interés de los brotes en la esclerosis múltiple. Fisiopatología y tratamiento

Revista de Neurologia

Volumn 36, Issue 11, 2003, Pages 1058-1064

  De Andrés, Clara ^a  

^a HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

Author keywords

Attack; Multiple sclerosis

Indexed keywords

CORTICOSTEROID; CORTICOTROPIN; DEXAMETHASONE; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; PREDNISONE; ANTIINFLAMMATORY AGENT; SEX HORMONE;

CENTRAL NERVOUS SYSTEM; CLINICAL OBSERVATION; DISEASE ACTIVITY; HORMONAL REGULATION; HORMONE ACTION; HUMAN; MULTIPLE SCLEROSIS; NERVE CELL PLASTICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PLASMAPHERESIS; REVIEW; SYMPTOMATOLOGY; WHITE MATTER; DISEASE COURSE; IMMUNOLOGY; INFECTION; METABOLISM; PATHOLOGY;

ADRENAL CORTEX HORMONES; ANTI-INFLAMMATORY AGENTS; CENTRAL NERVOUS SYSTEM; DISEASE PROGRESSION; GONADAL STEROID HORMONES; HUMANS; INFECTION; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; PLASMAPHERESIS;

EID: 0042306147     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3611.2002507     Document Type: Review

References (68)

1. Weinshenker BG. The natural history of multiple sclerosis. Neurol Clin North Am 1995; 13: 119-46.
2. Arbizu-Urdiain TX, Martinez-Yélamos S. Si tengo una esclerosis múltiple, ¿cuál es mi pronóstico? Continua Neurológica 1999; 2: 41-54.
3. Confabreux C, Vukusic S. Natural history of multiple sclerosis: implications for counselling and therapy. Curr Opin Neurol 2002; 15: 257-66.
4. Poser CM, Paty DW, Scheinberg L, McDonald WI, Davis FA, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
5. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001; 50: 121-7.
6. Lucchinetti C, Bruck W, Parisis J, Scheithauer B, Rodríguez M, Lassman H. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-17.
7. Peterson JW, Bö L, Mörk S, Chang A, Trapp B. Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis. Ann Neurol 2001; 50: 389-400.
8. Lucchinetti C, Brück W, Noseworthy J. Multiple sclerosis: recent developments in neuropathology, pathogenesis, magnetic resonance imaging studies and treatment. Curr Opin Neurol 2001; 14: 259-69.
9. Rodriguez-Sainz MC, Sánchez-Ramón S, de Andrés C, Rodríguez-Mahou M, Muñoz-Fernández MA. Th1/Th2 cytokine balance and nitric oxide in cerebrospinal fluid and serum from patients with multiple sclerosis. Eur Cytokine Netw 2002; 13: 110-4.
10. De Andrés C, Asensio MJ, Herranz AS, Cuadrado N. 14-3-3 testing in CSF is not sensitive to glutamate excitotoxicity in multiple sclerosis. Mult Scler 2001; 7 (Suppl 1): S35.
11. Werner P, Pitt D, Raine CS. Multiple sclerosis: altered glutamate homeostasis in lesions correlates with oligodendrocyte and axonal damage. Ann Neurol 2001; 50: 169-80.
12. Matute C, Alberdi E, Domercg M, Pérez-Cerdá F, Pérez-Sanmartín A, Sánchez-Gómez MV. The link between excitotoxic oligodendroglial death and demyelinating diseases. Trends Neurosci 2001; 24: 224-30.
13. Geurts JJ, Kamphorst W, Van der Valk, Aronica EM. Expression of metabotropic glutamate receptors in multiple sclerosis brain: upregulation in axon and reactive astrocytes. Mult Scler 2002; 8 (Suppl 1): S1-2.
14. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mörk S, Bö L. Axonal transection en the lesions of multiple sclerosis. N Eng J Med 1998; 338: 278-85.
15. Casanova B, Coret F, Valero C, Landete L, Pascual A, Vilchez JJ. High clinical inflammatory activity prior to the development of secondary progression: a prospective 5-year follow-up study. Mult Scler 2002; 8; 1-5.
16. Alvarez-Cermeño JC. Lesión axonal inicial en la esclerosis múltiple. Razones para un tratamiento precoz. Rev Neurol 2002; 35: 221-7.
17. Trojano M, Liguori M, Bosco Zimatore G, Bugarini R, Avolio C, Paolicelli D, et al. Age-related disability in multiple sclerosis. Ann Neurol 2002; 51: 475-80.
18. Dhabhar F, McEwen BS. Stress-induced enhancement of antigen-specific cell-mediated immunity. J Immunol 1996; 156: 2608-16.
19. Mohr DC, Goodkin ME, Bacchetti P, Boudewyn AC, Huang L, Marriett P, et al. Psychological stress and subsequent appearance of new brain MRI lesions in MS. Neurology 2000; 55: 55-61.
20. Buljevac D, Flach HZ, Hop CJ, Hijdra D, Laman JD, Savelkoul HFJ, et al. Prospective study on the relationship between infections and multiple sclerosis exacerbations. Brain 2002; 125: 952-60.
21. Soldan SS, Berti R, Salem N, Secchiero P, Flamand L, Clalbresi PA, et al. Association of human herpes virus 6 (HHV-6) with multiple sclerosis: increase IgM response to HHV-6 early antigen and detection of serum HHV-6 DNA. Nat Med 1997; 3: 1394-7.
22. Moore FGA, Wolfson C. Human herpes virus 6 and multiple sclerosis. Acta Neurol Scand 2002; 106: 63-83.
23. Álvarez-Lafuente R, Martín-Estefanía C, de las Heras V, Castrillo C, Picazo JJ, Varela de Seijas E, et al. Active human herpes virus 6 infection in patients with multiple sclerosis. Arch Neurol 2002; 59: 929-33.
24. Kim S, Liva SM, Dalal MA, Verity MA, Voskuhl RR. Estriol ameliorate autoimmune demyelinating disease. Implications for multiple sclerosis. Neurology 1999; 52: 1230-8.
25. Dalal M, Kim S, Voskuhl RR. Testosterone therapy ameliorates experimental autoimmune encephalomyelitis and induces a T helper 2 bias in the autoantige-specific T lymphocyte response. J Immunol 1997; 159: 3-6.
26. De Andrés C. Implicaciones inmunoneuroendocrinas en la patogenia de la esclerosis múltiple. Cuadernos de Esclerosis Múltiple 2001; 8: 24-33.
27. Duquette P. Hormonal factors in multiple sclerosis. MSJ 2002; 9: 17-25.
28. García-Segura LM, Chowen JA, Parduez A, Naftolin F. Gonadal hormones as promoters of structural synaptic plasticity: cellular mechanisms. Prog Neurobiol 1994; 44: 279-307.
29. Correale J, Arias M, Gilmore W. Steroid hormone regulation of cytokine secretion by proteolipid protein-specific CD4+ T cell clones isolated from multiple sclerosis patients and normal control subjects. J Immunol 1998; 161: 3365-74.
30. Kwon EE, Prineas JW. Blood-brain barrier abnormalities in longstanding multiple sclerosis lesions. An immunohistochemical study. J Neuropathol Exp Neurol 1994; 53: 624-36.
31. Thompson AJ, Miller D, Youl B. Serial gadolinium-enhanced MRI in relapsing-remitting multiple sclerosis of varying disease duration. Neurology 1992; 42: 60-3.
32. Rovira-Cañellas A. Resonancia magnética en el diagnóstico y manejo de la esclerosis múltiple. Neurología 2000; 15: 302-88.
33. Blamire AM. Actualités 10.° rendez-vous de l'ARSEP Paris, Palais des Congrés, 6 décembre 2000 Spectroscopie par résonance magnétique et affections démyélinisantes. Rev Neurol (Paris) 2002; 158; 263-7.
34. Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis. Brain 1997; 120: 393-9.
35. Waxman SG. Multiple sclerosis as a neuronal disease. Arch Neurol 2000; 57: 22-4.
36. Nathan C. Points of control in inflammation. Nature 2002; 420: 846-52.
37. Besedovsky HO, del Rey A. Immune-neuro-endocrine interactions: facts and hypotheses. Endocr Rev 1996; 17: 64-102.
38. Redford EJ, Kapoor R, Smith KJ. Nitric oxide donors reversible block axonal conduction: demielinated axons are especially susceptible. Brain 1997; 120: 2149-57.
39. Stuart L, Hughes J. Apoptosis and autoimmunity. Nefrol Dial Transplant 2002; 17: 697-70.
40. Magnus T, Chan A, Savill J, Toyka KV, Gold R. Phagocytotic removal of apoptotic inflammatory lymphocytes in the central nervous system by microglia and its functional implications. J Neuroimmunol 2002; 130: 1-9.
41. Arnold DL, Matthews PM. MRI in the diagnosis and management of multiple sclerosis. Neurology 2002; 58 (Suppl 4): S23-31.
42. Pantano P, Iannetti GD, Caramia F, Mainero C, Di Legge S, Bozazo L, et al. Cortical motor reorganisation after a single clinical attack of multiple sclerosis. Brain 2002; 125: 1607-15.
43. De Andrés C, Gil R, López L, Salinero E, Bittini A. Nonpainful phantom sensation, illusory limb movement in a patient with dorsal myelitis. Neuropathological and SPECT finding. J Neurol 2002; 249: 930-2.
44. Rocca MA, Falini A, Colombo B, Scotti G, Comi G, Filippi M. Adaptive functional changes in the cerebral cortex of patients with nondisabling multiple sclerosis correlate with the extent of brain structural damage. Ann Neurol 2002; 51: 330-9.
45. Compston A, Coles A. Multiple sclerosis. Lancet 2002; 359: 1221-31.
46. Stadelmann C, Kerschensteiner M, Misgeld T, Brück W, Hohfeld R, Lassmann H. BDNF and 145trkB in multiple sclerosis brain lesions: neuroprotective interactions between immune and neuronal cells? Brain 2002; 125: 75-85.
47. Harkness KA, Adamson P, Sussman JD, Davis-Jones AB, Greenwood J, Woodroofe MN. Dexamethasone regulation of matrix metalloproteinase expression in CNS vascular endothelium. Brain 2000; 123; 698-709.
48. Andersson P, Goodkin D. Glucocorticosteroid therapy for multiple sclerosis: a critical review. J Neurol Sci 1998; 160: 16-25.
49. Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomised controlled clinical trials. J Neurol 2000; 247: 435-42.
50. Leussink VI, Jung S, Merschdorf U, Toyka KV, Gold T. High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes. Arch Neurol 2001; 58: 91-7.
51. Liu Y, Cousin JM, Hughes J, Damme JV, Seckl JR, Haslett CH, et al. Glucocorticoids promote nonflogistic phagocytosis of apoptotic lickcities. J Immunol 1999; 162: 3639-46.
52. Keles MS, Taysi S, Sen N Akcay F. Effects of corticosteroid therapy on serum and CSF malondialdhehyde and antioxidant proteins in multiple sclerosis. Can J Neurol Sci 2001; 28: 141-3.
53. Zivadinov R, Rudick RA, De Masi R, Nauselli D, Ukmar M, Puzzi-Mucelli RS, et al. Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS. Neurology 2001; 57: 1239-47.
54. Olivieri RL, Valentino P, Russo C, Sibilia G, Aguglia U, Bono F, et al. Randomised trial comparing two different high doses of methylprednisolone in MS: a clinical and MRI study. Neurology 1998; 50: 1833-6.
55. Barkoff F, Hommes OR, Schelstens P, Valk J. Quantitative MRI changes in Gadolinium-DPTA enhancement after high-dose intravenous methylprednisolone in multiple sclerosis. Neurology 1991; 41: 1219-22.
56. Harris TO, Frank JA, Patronas N, McFarlin DE, McFarland HF. Serial gadolinium enhanced magnetic resonance imaging scans in patients with early, relapsing remitting multiple sclerosis: Implications for clinical trials and natural history. Ann Neurol 1991; 29: 548-55.
57. Warren KG, Catz I, Verona MJ, Carroll DJ. Effect of methylprednisolone on CSF IgG parameters, myelin basic protein and anti-myelin basic protein in multiple sclerosis exacerbations. Can J Neurol Sci 1986; 13: 25-30.
58. Sellebjerg F, Frederiksen JL, Nielsen PM, Olensen J. Double-blind, randomised, placebo-controlled study of oral high dose methylprednisolone in attacks of MS. Neurology 1998; 51: 529-34.
59. Alam SM, Kyriakides T, Lawden M, Newman PK. Methylprednisolone in multiple sclerosis: a comparison of oral with intravenous therapy at equivalent high dose. J Neurol Neurosurg Psychiatry 1993; 56: 1219-20.
60. Rose AS, Kuzma JW, Kurtzke JF, Namerow NS, Sibley WS, Tourtellotte WW. Cooperative study in the evaluation of therapy in multiple sclerosis: ACTH vs. placebo. Final report. Neurology 1970; 20: 1-19.
61. Barnes D, Hughes RA, Morris RW, Wade-Jones O, Brown P, Britton T, et al. Randomised trials of oral and intravenous methylprednisolone in acute relapses of multiple sclerosis. Lancet 1997; 349: 902-6.
62. La Mantia L, Eoli M, Milanese C, Salmaggi A, Dufour A, Torri V. Double-blind trial of dexamethasone versus methylprednisolone in multiple sclerosis acute relapses. Eur Neurol 1994; 34: 199-203.
63. Compston DAS. Dexamethasone protects neurons against microglial toxicity. J Neurol 2002; 248 (Suppl 1): 165-648.
64. Vgontzas AN, Chrousos GP. The hypothalamic-pituitary-adrenal axis and cytokines: multiple interactions and disturbances in sleep disorders. Endocrinol Metab Clin Nort Am 2002; 31: 15-36.
65. Weinshenker BG, O'Brien PC, Ptterson TM. A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease. Ann Neurol 1999; 46: 878-86.
66. Keegan M, Pineda AA, McClelland RL, Darby CH, Rodríguez M, Weinshenker BG. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 2002; 58: 143-6.
67. Tagawa Y, Yuki N, Hirata K. Ability to remove immunoglobulins and anti-ganglioside antibodies by plasma exchange, double-filtration plasmapheresis and immunoadsorption. J Neurol Sci 1998; 157: 90-5.
68. De Andrés C, Anaya F, Giménez-Roldán S. Tratamiento con plasma inmunoadsorción en brotes severos y prolongados de esclerosis múltiple maligna. Rev Neurol 2000; 30: 601-5.